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A B S T R A C T   
Background: Treatment resistant depression (TRD) characterizes a subgroup of 10–30% of patients with major depressive disorder, and is associated with considerable 
morbidity and mortality. A consensus treatment for TRD does not exist, which often leads to wide variations in treatment strategies. Real-world studies on treatment 
patterns and outcomes in TRD patients in Europe are lacking and could help elucidate current treatment strategies and their efficacy. 
Methods: This non-interventional cohort study of patients with TRD (defined as treatment failure on ≥2 oral antidepressants given at adequate dose and duration) 
with moderate to severe depression collected real-world data on treatment patterns and outcomes in several European countries. Patients were started on a new 
treatment for depression according to routine clinical practice. 
Results: Among 411 patients enrolled, after 6 months, only 16.7% achieved remission and 73.5% showed no response. At Month 12, while 19.2% achieved remission 
and 69.2% showed no response, 33.3% of those in remission at Month 6 were no longer in remission. Pharmacological treatments employed were heterogenous; 54 
different drugs were recorded at baseline, and the top 5 treatment types according to drug classes accounted for 40.0% of patients. Even though remission rates were 
very low, at Month 12, 60.0% of patients had not changed treatment since enrolment. 
Conclusions: The heterogeneity of treatments highlights a lack of consensus. Moreover, despite low response rates, patients often remained on treatments for sub-
stantial periods of time. These data further support existence of an unmet treatment need for TRD patients in Europe.   
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Author Interview, Animated Summary and Plain Language 
Summary 
To view an interview with one of the authors, Professor Giulio 
Perugi, summarizing this publication, please see the video below, or visit 
the manuscript on line at doi:10.1016/j.jad.2021.03.073. 
PLAIN LANGUAGE SUMMARY 
What is Treatment Resistant Depression? 
Major depressive disorder (MDD) is a debilitating condition that 
affects up to 10% of the general population during their lifetime. A 
diagnosis of MDD requires five or more symptoms of depression, 
including depressed mood, loss of interest or pleasure in most or all 
activities, fatigue, sleeping excessively or insomnia, inability to 
concentrate or make decisions, over eating or loss of appetite, and 
feelings of worthlessness, when those symptoms cause significant 
distress and last at least two weeks. In addition to making patients feel 
extremely unwell, MDD reduces people’s ability to function in everyday 
activities at work and at home and is also associated with suicide. Once, 
within the same episode of depression, two different antidepressive 
treatments have not led to improvement, patients are diagnosed with 
‘treatment resistant depression’, or TRD, which affects between 10 and 
30% of patients with MDD. Among the many treatments approved for 
MDD, there is very little information about which are used to treat TRD 
patients across Europe and how effective the different treatments are. As 
a result, it is difficult to understand how TRD is best treated, and patients 
often have to try many different treatments to find one that works. 
What was this study investigating? 
Our study looked at the treatments currently prescribed to patients 
with TRD in several European countries, and whether the treatments are 
effective. We identified 411 patients with TRD who were starting a new 
treatment, and followed them for at least 6 months, to record if their 
symptoms improved. Data were collected from medical records, with 
assessments completed by specialist clinicians. Patients also completed 
questionnaires rating the severity of their symptoms and how they 
affected their quality of life and ability to do tasks at work and at home. 
What did the results of the study show? 
The study found many different treatments were prescribed to the 
patients, including combinations of medications as well as single drugs. 
In a small number of patients, psychological treatments (ie ‘talking’ 
therapies) and brain stimulation therapies were also used. Most often, an 
antidepressant (eg selective serotonin reuptake inhibitor [SSRI] or se-
rotonin and norepinephrine reuptake inhibitor [SNRI]) was prescribed 
with a non‑antidepressant ‘add-on’ treatment (including antipsychotics, 
or mood stabilizers), but it was also common for patients to be pre-
scribed two antidepressants together. After 6 months, 73.5% of patients 
had not responded to treatment, and at 12 months, 69.2% of patients 
had still not responded. Of the patients who had responded at 6 months 
and were re‑assessed at 12 months, symptoms had returned in more than 
half. Despite such low levels of response, after 12 months of treatment 
only 40.0% of patients had changed treatment strategy and 60.0% were 
still on the same drug strategy that was prescribed when they enrolled in 
the study. 
What are the key findings from the study? 
Despite the many different treatments prescribed, most patients had 
not improved after 12 months. Many who had initially shown 
improvement with treatment found their symptoms returned later, so 
the beneficial effects of the treatment did not last long. Surprisingly, 
most patients stayed on their initial drug combination, even though 
many were not improving and treatment could be changed at any time. 
Were there any limitations to the study? 
Limitations of the study were the absence of a control group for 
comparison (so the results cannot be compared to what might have 
happened in patients not starting a new treatment), and the fact that a 
considerable number of patients did not have all the assessments 
completed during the study. 
What are the wider implications of the study? 
This study shows that treatment strategies prescribed across Europe 
lack effectiveness in most patients with TRD. So far, only one drug 
combination, an SSRI or SNRI plus esketamine nasal spray, has specific 
approval in Europe for treating TRD. However, research into other po-
tential treatments is ongoing, providing future prospects for additional 
treatments for these patients. 
1. Introduction 
Major depressive disorder (MDD) is a debilitating condition that 
results in considerable morbidity and mortality, in part due to high 
suicide risk (Cavanagh et al., 2003). MDD is thought to affect 4–10% of 
the general population across their lifetime (National Institute for 
Health and Care Excellence, 2020) and depressive disorders are a 
leading cause of disability (James et al., 2018). Approximately 10–30% 
of patients with MDD have treatment resistant depression (TRD) (Rush 
et al., 2006b; Jaffe et al., 2019; Al-Harbi et al., 2012; Voinescos et al., 
2020), defined as a major depressive episode (MDE) that fails to respond 
to two or more different antidepressants, given at adequate dose and 
duration (European Medicines Agency, 2013; Souery et al., 1999). Other 
definitions of TRD have also been used, precluding consensus on the 
prevalence of the condition (Wiles et al., 2014; Conway et al., 2017; 
Nemeroff et al., 2007). 
Current treatments for MDD include medication, psychological and 
neurostimulation therapies (National Institute for Health and Care 
Excellence, 2020; European Medicines Agency, 2013; Cleare et al., 
2015). Clinical management of TRD can include different combinations 
of these treatments, including antidepressant and non-antidepressant 
drugs, as well as non-pharmacological therapies (European Medicines 
Agency, 2013; Voineskos et al., 2020; Bennabi et al., 2019; Ionescu 
et al., 2015). All antidepressant drugs can be used in the treatment of 
TRD including selective serotonin reuptake inhibitors (SSRIs), dual se-
rotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic anti-
depressants (TCA), monoamine oxidase inhibitors (MAOIs), and ‘other’ 
antidepressants such as tianeptine, agomelatine and α2-antagonists 
(Ionescu et al., 2015; Kim et al., 2019; Tobe and Rybakowski, 2013). 
Medications without primary antidepressant properties can also be used 
in the treatment of TRD to potentiate the effects of an antidepressant 
drug. These include lithium, thyroid hormone and antipsychotics such 
as quetiapine (Bauer et al., 2013). Pharmacological treatment strategies 
for TRD can be categorized as switching (from one antidepressant to 
another); combination therapy (adding another antidepressant to the 
current one); and augmentation/add-on therapy (use of a 
non-antidepressant medication in addition to a current antidepressant) 
(Barowsky and Schwartz, 2006; Ionescu et al., 2015; Voineskos et al., 
2020). Non-pharmacological (psychotherapeutic and neurostimulatory) 
therapies, have also been developed for TRD (Voineskos et al., 2020; 
van Bronswijk et al., 2019; Lefaucheur et al., 2020; Lisanby, 2007) but 
will not be discussed in detail here. 
While treatment patterns and outcomes in patients with TRD in 
clinical practice have been studied in the US (Kubitz et al., 2013; Amos 
et al., 2018), recent research in Europe is limited. The US Sequenced 
Treatment Alternatives to Relieve Depression (STAR*D) trial is the 
largest multistep treatment study of patients with depression to date and 
provided key insights into treatment failure in the clinical setting (Rush 
et al., 2006b). STAR*D showed that most patients with TRD fail to 
achieve remission with current treatments. Remission rates of approxi-
mately 33%, 25–33%, 14% and 13% were achieved during the first, 
second, third and fourth treatment steps in the study, respectively, 
leading the authors to suggest that the likelihood of remission is reduced 
in patients with TRD (equating to those reaching steps three and four). In 
patients that achieved remission, loss of response was common; 60% of 
TRD patients that responded to treatment became unresponsive to 
treatment within 6 months. A prospective, 2-year observational study of 
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patients with TRD being treated in routine clinical practice, reported a 
12-month remission rate of 3.6% . Loss of remission between Month 12 
and 24 occurred in 75% of patients, highlighting that maintenance of 
therapeutic effect is poor (Dunner et al., 2006). Data from European 
patients, although limited, suggest similar outcomes. In a study in the 
UK, the 18-month remission rate for patients with TRD receiving treat-
ment as usual, as directed by their primary care practitioner, was 6.5% 
and dropped to 4.4% at 42-month follow up (Fonagy et al., 2015). 
Regarding European-wide market approval, a single pharmacolog-
ical treatment, esketamine nasal spray (in combination with an SSRI or 
SNRI) was the first treatment approved for TRD specifically (European 
Medicines Agency, 2013; Mahase, 2019; European Medicines Agency, 
2019). Importantly, however, it was not approved until after this study 
ended (European Medicines Agency, 2013; Mahase, 2019; European 
Medicines Agency, 2019). Additionally, there is no consensus on treat-
ment pathways for TRD, and evidence suggests wide variation between 
and within European countries (MacQueen et al., 2017). The current 
cohort study was established to collect data from TRD patients with 
moderate to severe depression being treated in routine clinical practice 
in a sample of European countries. The aim of the study was to describe 
real-world clinical features and, as such, did not include a specific hy-
pothesis. Treatment patterns and outcomes were followed for up to 21 
months in patients starting a new therapy, having already experienced 
at least two treatment failures in the current MDE. The objectives of the 
study were to describe the disease-related and socio-demographic 
characteristics and disease burden of TRD patients in Europe; treat-
ment patterns used to manage TRD in European clinical practice, and the 
resulting clinical outcomes; and healthcare resource utilisation associ-
ated with TRD. The baseline characteristics of the patient cohort have 
been published recently, demonstrating that patients had low 
health-related quality of life (HRQoL) and reduced function (Heerlein 
et al., 2021). This paper reports data supporting the second objective, 
focusing on treatment patterns and clinical outcomes among patients 
from this cohort. 
2. Methods 
2.1. Patients 
Patients aged 18 to 74 years fulfilling the criteria for TRD were 
eligible. A diagnosis of MDD (fulfilling the Diagnostic and Statistical 
Manual of Mental Disorders Fifth Edition [DSM-5] or the International 
Statistical Classification of Diseases and Related Health Problems, Tenth 
Revision [ICD-10] criteria for MDD or Depressive disorder) was required 
for inclusion (European Medicines Agency, 2013), as well as a Mont-
gomery-Åsberg Depression Rating Scale (MADRS; Montgomery and 
Asberg, 1979) score ≥20, indicating moderate to severe depression. TRD 
was defined by treatment failure (≤25% improvement on best day) on 
≥2 different oral antidepressants, taken for ≥6 weeks, at adequate dose 
in the same MDE, as determined using the Massachusetts General 
Hospital-Antidepressant Treatment Response Questionnaire 
(MGH-ATRQ; Chandler et al, 2010). 
For inclusion, patients needed to be starting a new antidepressant 
treatment, as an inpatient or outpatient. Treatment was according to 
routine clinical practice in that setting; choice of treatment, dose and 
method of administration was at the discretion of the treating physician. 
In the context of the study, any pharmacological or non- 
pharmacological treatment, including neurostimulation and psycho-
therapeutic interventions, prescribed to replace, or in addition to, the 
previous treatment, was considered a new antidepressant treatment. 
Switches to a generic drug or changes in dose did not count as a new 
treatment. 
The following were exclusion criteria: current or prior diagnosis of 
psychotic disorders, MDD with psychotic features, bipolar disorders or 
intellectual disability according to DSM-5 or ICD-10; history of suicidal 
behavior within one year prior to enrolment; homicidal ideation or 
intent, or suicidal ideation or intent, within one month prior to entering 
the study; moderate to severe substance misuse (including alcohol) 
within six months before enrolment. Written informed consent was 
provided by all participants, and their capability for doing so was judged 
by the treating physician. Local ethics review boards provided approval 
for the study, which adhered to the Declaration of Helsinki. 
2.2. Study design 
A prospective, multicenter, observational cohort study of patients 
with TRD in Europe was conducted. The study has been described in 
detail elsewhere (Heerlein et al., 2021). Briefly, the study was comprised 
of baseline data collection, a 12-month observational period with a 
minimum follow-up of approximately 6 months for each enrolled pa-
tient, and an extended observation period up to 6 months from 
recruitment of the last patient, resulting in a maximum of 21 months of 
follow-up. Analysis was conducted only on data collected at 6 and 12 
months after baseline (Supplementary Fig. 1). Patients were enrolled 
from Belgium, Germany, Italy, the Netherlands, Portugal, Spain and the 
United Kingdom. 
2.3. Treatments 
Antidepressant treatments (pharmacological, psychotherapeutic and 
neurostimulatory) prescribed on enrolment and during the observa-
tional period were documented in medical records. Pharmacological 
treatment strategies were categorized as monotherapy, combination 
therapy or augmentation therapy. Treatment could be changed at any 
time during the study, at the discretion of the treating physician. 
2.4. Study procedures and evaluations 
Data were collected at baseline, on scheduled visits every 6 months 
and at the end of the study, which was planned to run until 6 months after 
enrolment of the last patient. The data collection planned for the end of 
the study was also performed in the event of a patient leaving the study 
before the end of the observational period and, for patients who withdrew 
consent, were lost to follow-up or died before the end of the study, as 
many data were collected as possible. Additional data collection was 
encouraged in case of clinically relevant events, namely: admission to, or 
discharge from, inpatient settings; relapse of symptoms (including sui-
cidal ideation/intent/behavior); remission of the current MDE (as 
confirmed by MADRS ≤10); visit/consultation with treating physician 
due to worsening or improvement of the current MDE (confirmed by 
Clinical Global Impression of Change [CGI-C; Busner and Targum, 2007] 
≤3 or ≥5); change in pharmacological treatment (medication switch; 
dose changes except those relating to titration during switching; start of 
augmentation therapy); change in non-pharmacological treatment. 
Baseline data were collected on patient socio-demographics, disease 
history and current clinical characteristics as well as details of all anti-
depressant treatments used in the current MDE prior to study entry. 
Assessment at any visit could include documentation of: spectrum and 
severity of depression symptoms (MADRS; Clinical Global Impression of 
Severity [CGI-S] score); change in depression severity since initiating last 
treatment (CGI-C score); suicidality (Columbia Suicide Severity Rating 
Scale; Posner et al., 2011); HRQoL (EuroQoL 5-dimension 5-level 
[EQ-5D-5L] patient-reported questionnaire, including the EuroQoL Vi-
sual Analog Scale [EQ-VAS]; Herdman et al., 2011); functional impair-
ment or disability in and outside of work (Work Productivity and Activity 
Impairment [WPAI; Reilly et al., 1993] and the Sheehan Disability Scale 
[SDS; Sheehan et al., 1996] patient-reported questionnaires). 
2.5. Data processing and statistical analysis 
The remission or response status of each patient (irrespective of 
treatment strategy) was assessed at 6 and 12 months after baseline, 
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according to MADRS scores. Remission was defined as a score ≤10, while 
scores >10 but with improvement from baseline ≥50% defined response 
without remission. Visits were considered as occurring in Month 6 if they 
occurred 150–216 days after enrolment, while Month 12 visits were 
defined as those occurring 330–402 days after enrolment. Data obtained 
outside these windows were excluded from the relevant time point. 
Treatment steps for each patient were reconstructed by matching 
MADRS scores to the start and end dates of each treatment strategy (dates 
and treatments obtained from medical records), with the end represent-
ing a change to a different treatment strategy. Only pharmacological 
treatment strategy changes were considered in the treatment strategy 
analysis, excluding any <30 days duration. The MADRS values at the start 
and end of each treatment strategy were used to determine whether the 
patient had experienced remission, response without remission, or no 
response. When the MADRS score was not available, a response/remis-
sion proxy was inferred based on CGI scores, to increase the number of 
treatment strategies for which a corresponding treatment outcome could 
be reported. If the end CGI-S score was 1 or 2 (out of 7, with higher scores 
indicating greater severity), the treatment strategy was considered to 
have resulted in remission (Turrina et al., 2015). When this was not the 
case, yet the CGI-C score was 1 or 2 (out of 7, where the lowest scores 
indicate substantial improvement and scores >4 indicate a worsening 
condition) then the treatment strategy was considered to have resulted in 
response without remission (Fava et al., 2017). 
Continuous variables were summarized using descriptive statistics 
(N, mean, standard deviation [SD], median, minimum and maximum). 
Categorical variables were summarized by frequency distribution 
(number and percentage of patients in each category). Significance 
testing of data stratified by outcome (remission, response without 
remission, and non-response) was carried out first by using a Kruskal 
Wallis (KW) test to evaluate the null hypothesis that data from all three 
outcome groups were equal. If the KW test indicated a significant dif-
ference, it was followed by post-hoc Dunn’s tests comparing the data 
between each of the three outcome groups. A p value <0.05 was 
considered significant. Treatment strategy duration by response status 
was compared using a repeated-measures model using SAS proc mixed 
procedure. The model statement included categorical variables for 
response status (two categories: response, no response) along with 
treatment strategy number at baseline (three categories: first step, sec-
ond step, third step or higher). To account for within-subject correlation 
of treatment strategy duration, a repeated-measures statement with 
unstructured covariance matrix was included. The p value 
Fig. 1. MADRS responses at Month 6 and 
Month 12. A. Patient outcomes at Month 6 and 
12 (total population). B. Patient outcomes at 
Month 12, by remission status at Month 6. C. 
Patient outcomes at Month 12, by response 
status at Month 6. Dataset includes all patients, 
irrespective of treatment strategy. Only patients 
with MADRS scores for both Month 6 and 12 
were included in B and C. Remission: MADRS 
score ≤10; response: MADRS improvement 
from baseline ≥50%; response without remis-
sion: MADRS improvement from baseline 
≥50% and MADRS score >10; no response: 
MADRS improvement from baseline <50% and 
MADRS score >10. MADRS: Montgomery- 
Åsberg Depression Rating Scale.   
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corresponding to the response status factor in the model statement was 
evaluated for significance. Time-to-treatment strategy change analysis 
was performed by Kaplan-Meier time-to-event analysis. 
3. Results 
3.1. Baseline characteristics and treatments 
The final analysis set included 411 eligible patients (Supplementary 
Table 1). The mean (SD) age of patients was 51.0 (10.8) years and 
62.3% were female. The mean (SD) MADRS score was 31.8 (6.0) and 
67.4% of patients had moderate depression (MADRS 20–34); the 
remainder (32.6%) had severe depression (MADRS >34). In the current 
MDE, 53.8%, 31.1% and 14.6% of patients had experienced two, three 
or four or more treatment failures, respectively. At baseline, 343/411 
(83.4%) patients were taking at least one pharmacological treatment. 
Psychotherapeutic treatment and neurostimulation therapy were being 
prescribed to 19.2% and 6.6% of patients, respectively. A full 
description of the baseline characteristics of this patient population has 
been published previously (Heerlein et al., 2021). 
3.2. Overall treatment outcomes at Month 6 
At Month 6, 58 patients were reported as discontinued: 1 patient 
ended the study after 99 days1; 37 patients were lost to follow up; 7 
withdrew consent; 3 died; 9 discontinued due to ‘other’ reasons; 1 was of 
unknown status. Data were excluded from a further 47 patients who 
were still in the study at Month 6, but whose visits did not meet the 
defined cut-off dates for a Month 6 visit. All other patients were included 
in this analysis, irrespective of treatment strategy. Of these patients, 
73.5% showed no response, 9.8% showed response without remission 
Table 1 



















CGI-C score, n (%) 
Very much improved 28 (9.2) 2 (0.9) 2 (6.7) 24 (47.1) 
Much improved 73 (23.9) 31 (13.8) 16 (53.3) 26 (51.0) 
Minimally improved 92 (30.1) 82 (36.4) 9 (30.0) 1 (2.0) 
No change 73 (23.9) 71 (31.6) 2 (6.7) 0 
Minimally worse 25 (8.2) 24 (10.7) 1 (3.3) 0 
Much worse 15 (4.9) 15 (6.7) 0 0 


















Dataset includes all patients, irrespective of treatment strategy. *p<0.05; **p<0.01; ***p<0.001 when compared to no response (Kruskal Wallis test followed by post- 
hoc Dunn’s test). Remission: MADRS score ≤10; response without remission: MADRS improvement from baseline ≥50% and MADRS score >10. CGI-C: Clinical Global 
Impression of Change scale; EQ-5D-5L: European Quality of Life (EuroQol)-5-dimension 5-level; EQ-VAS: EuroQol-visual analog scale; MADRS: Montgomery-Åsberg 
Depression Rating Scale; SD: standard deviation; SDS: Sheehan Disability Scale. 
Table 2 



















CGI-C score, n (%) 
Very much improved 20 (13.7) 1 (1.0) 4 (23.5) 15 (53.6) 
Much improved 29 (19.9) 13 (12.9) 7 (41.2) 9 (32.1) 
Minimally improved 43 (29.5) 38 (37.6) 3 (17.6) 2 (7.1) 
No change 34 (23.3) 31 (30.7) 2 (11.8) 1 (3.6) 
Minimally worse 13 (8.9) 11 (10.9) 1 (5.9) 1 (3.6) 
Much worse 6 (4.1) 6 (5.9) 0 0 


















Dataset includes all patients, irrespective of treatment strategy. *p<0.05; **p<0.01; ***p<0.001 when compared to no response (Kruskal Wallis test followed by post- 
hoc Dunn’s test). Remission: MADRS score ≤10; response without remission: MADRS improvement from baseline ≥50% and MADRS score >10. CGI-C: Clinical Global 
Impression-Change scale; EQ-5D-5L: European Quality of Life (EuroQol)-5-dimension 5-level; EQ-VAS: EuroQol-visual analog scale; MADRS: Montgomery-Åsberg 
Depression Rating Scale; SD: standard deviation; SDS: Sheehan Disability Scale. 
1 Whilst the protocol recommended a minimum of 6 months follow-up, this 
patient was reported to have ended the study after 99 days, even though the 
study was on-going. No data from this patient were recorded after 99 days, so 
their data are not included in 6 or 12-month analyses. 
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and 16.7% were in remission (Fig. 1A). As per the definitions used to 
stratify patients by outcome status, the mean (SD) MADRS score for 
patients achieving remission was 6.0 (2.6) compared to 14.1 (2.7) in 
patients with response without remission and 26.2 (7.5) in patients with 
no response (Table 1). Using KW tests followed by post-hoc Dunn’s tests 
to analyse mean change from baseline, greater change was seen across 
EQ-5D-5L, EQ-VAS and SDS in patients achieving remission compared to 
those with no response (p<0.001 for all comparisons; Table 1). Greater 
mean change was also observed for patients achieving response without 
remission in the same comparison (p<0.05 or p<0.01; Table 1). 
3.3. Overall treatment outcomes at Month 12 
At Month 12, 244 patients in total were not included in the analysis 
set: for 164 patients the study ended prior to their 12-month assessment; 
45 were lost to follow up; 9 withdrew consent; 4 died; 22 discontinued 
due to ‘other’ reasons; 1 was of unknown status. Data were excluded 
from a further 21 patients who were still in the study at Month 12, but 
whose visits did not meet the defined cut-off dates for a Month 12 visit. 
All other patients were included in this analysis, irrespective of treat-
ment strategy. Of these patients, 69.2% had not responded, 11.6% 
showed response without remission and 19.2% were in remission 
(Fig. 1A). Using KW tests followed by post-hoc Dunn’s tests to analyse 
mean change from baseline, greater changes in EQ-5D-5L, EQ-VAS and 
SDS were observed in patients who had achieved remission at Month 12 
than for those who had not responded (p<0.001; Table 2), and changes 
in EQ-5D-5L and EQ-VAS were greater in patients achieving response 
without remission when compared to those with no response (p<0.05; 
Table 2). 
3.4. Changes in remission or response status between Month 6 and 12 
Maintenance of remission or response was analysed in patients for 
whom data at both timepoints were available. Of patients who had not 
achieved remission at Month 6, 86.6% of those that were assessed again 
at Month 12 still had not achieved remission (Fig. 1B). Among patients 
who achieved remission at Month 6, 33.3% of those that were assessed 
again at Month 12 were no longer in remission (Fig. 1B). When these 
patients were stratified by response vs non-response, 51.7% of Month 6 
responders had lost response by Month 12, and among non-responders 
at Month 6, 72.9% remained unresponsive at Month 12 (Fig. 1C). 
3.5. Treatment patterns and response by number of treatments since 
enrolment 
Data from patients taking ≥1 pharmacological treatment with a 
duration ≥30 days were included in this analysis. The rate of response to 
treatment increased with the number of treatment changes after base-
line (Fig. 2A). With treatment implemented at baseline, 26.4% of pa-
tients responded, while response was achieved in 35.5% of patients 
completing a third treatment since entering the study (Fig. 2A). For 
baseline treatment, the proportions of patients on combination or 
augmentation strategies were 35.4% and 36.7%, respectively, 23.2% 
were on monotherapy (Fig. 2B). The proportion of patients on a mon-
otherapy decreased as treatment was changed, with 16.7% on mono-
therapy in the third treatment since starting the study (Fig. 2B). There 
was a concurrent increase in the percentage of patients on augmentation 
therapy that accounted for 50.0% of patients completing a third treat-
ment since starting the study (Fig. 2B). 
Fig. 2. Pharmacological strategies and treatment outcomes per 
treatment step during the study. A. Treatment outcomes by 
treatment step during the study from baseline. B. Pharmaco-
logical strategies per treatment step during the study from 
baseline; data include only patients that were taking ≥1 
pharmacological treatment and who had been taking it for ≥30 
days. All patients have already experienced at least two treat-
ment line failures prior to study entry, as per study inclusion 
criteria; since the number of treatment lines prior to enroll-
ment varies across the cohort, the number of treatment 
changes does not necessarily relate to the total number of 
treatment lines a patient has been prescribed. Figure shows 
results from the total population. *Add-on drug only therapy: 
prescription of an add-on medication in the absence of regular 
oral antidepressant(s). Augmentation therapy: prescription of 
an add-on medication in addition to regular oral antidepressant 
(s). Combination therapy: prescription of ≥2 antidepressant 
medications. Monotherapy: prescription of 1 antidepressant 
medication. Remission: MADRS score ≤10; response without 
remission: MADRS improvement from baseline ≥50% and 
MADRS score >10; no remission: MADRS improvement from 
baseline <50% and MADRS score >10. MADRS: Montgomery- 
Åsberg Depression Rating Scale.   
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Together, the top five treatments, taken by patients at baseline 
defined according to drug classes, accounted for 40.0% of all treatments 
used at that timepoint (Fig. 3A). The most common treatment at baseline 
was the combination of an SNRI plus “other” antidepressant, used in 
11.0% of patients. “Other” antidepressants as monotherapy and SSRI 
plus “other” antidepressant were both taken by 8.2% of patients 
(Fig. 3A). In patients whose treatment was changed following failure of 
baseline treatment, the top two individual treatment classes taken on 
changing were SNRIs (8.3%) and SSRIs (6.5%) both used as a mono-
therapy (Fig. 3B). The top two treatment classes and combinations used 
for patients changing treatment a second time in the study were a 
combination of SSRI plus “other” antidepressant plus an add-on drug 
(11.1%) and an SNRI plus add-on medication (8.3%; Fig. 3C). 
3.6. Treatment strategy duration, per treatment strategy used since 
baseline 
Data from 392 treatment strategies were available for analysis, after 
excluding non-pharmacological strategies. Of these, outcomes (remission, 
response, non-response) were assigned based on CGI-S and/or CGI-C in 
3.6% (14/392) of treatment strategies where a corresponding MADRS 
score was not available. Pharmacological strategies ≥30 days duration 
were analysed. Where a treatment strategy resulted in response (including 
remission), the mean (SD) duration of treatment was 250.6 (136.0) days. 
When patients did not achieve a response, the mean (SD) treatment 
strategy duration before changing was shorter (196.2 [128.3] days; 
p<0.001; repeated measures model; Fig. 4A). Kaplan-Meier analysis was 
used to analyse time-to-treatment change endpoints. After approximately 
6 months of treatment, 68.4% of patients had not changed treatment 
strategy (including prescription of an additional drug) since enrolment. At 
Month 12, approximately 60.0% of patients had not changed their 
treatment strategy since entry into the study (Fig. 4B). 
4. Discussion 
This study assessed the naturalistic treatment patterns and clinical 
outcomes of 411 patients with TRD in Europe. Results at 6 months after 
initiating a new treatment strategy, as per routine clinical practice, 
showed most patients did not respond to treatment or achieve remission, 
remained very unwell and had poor HRQoL and reduced function. The 
number of different treatment strategies reported was high; the top five 
treatment types accounted for only 40.0% of treatments, suggesting that 
current treatment strategies employed for patients with TRD are very 
heterogeneous. Importantly, and considering that there is no consensus 
Fig. 3. Treatment strategies used at each 
treatment step, by treatment classes. *Add-on 
drug only therapy: the use of an add-on medi-
cation in the absence of regular oral antide-
pressant(s). A. Baseline treatment. B. Treatment 
after first treatment change in the study. C. 
Treatment after second treatment change in the 
study. All patients have already experienced ≥2 
treatment line failures prior to study entry, as 
per study inclusion criteria. Augmentation 
therapy: the prescription of an add-on medica-
tion in addition to regular oral antidepressant 
(s). Combination therapy: the prescription of 
≥2 antidepressant medications. Figure shows 
most common treatment classes prescribed in 
≥2%, ≥5% and >2 patients (A, B and C, 
respectively). SNRI: serotonin-norepinephrine 
reuptake inhibitor; SSRI: selective serotonin 
reuptake inhibitor; TCA: tricyclic 
antidepressant.   
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strategy across Europe for treating TRD, the wide variation in treatment 
strategies being used in clinical practice makes it difficult to build a 
robust evidence base of which strategies are most efficacious to inform 
clinical guidelines. This, in turn, makes it more challenging for clinicians 
to make informed treatment decisions. 
The results reported here largely align with other studies, in terms of 
the variety of treatments used and treatment outcomes (Rush et al., 
2006b, Ionescu et al., 2015). 
In this study, most patients failed to achieve or sustain a clinical 
response, with less than 20% of patients in remission at 12 months. In a 
2-year observational study of patients with TRD in which patients 
received a variety of treatments (‘treatment as usual’), that could be 
changed at any time during the study, a 12-month remission rate of 3.6% 
was reported (Dunner et al., 2006). This is considerably lower than the 
remission rate observed in the current study. Notable differences that 
may have contributed towards the lower remission rate include the in-
clusion of patients with bipolar disorder, higher number of mean 
treatment failures and longer mean duration of the current MDE, indi-
cating a cohort with more difficult to treat depression. Furthermore, in 
that study the self-rated 30-item Inventory of Depressive 
Symptomatology-Self-Report was used to assess changes in the degree of 
depression. Other studies of long-term outcomes for TRD patients in 
routine clinical practice have also reported lower remission rates than 
the current study. As in this study, the US Treatment-Resistant Depres-
sion Registry study (Aaronson et al., 2017) used clinician rated assess-
ments (MADRS), and the baseline depression severity was comparable. 
However, only 12% of patients achieved remission after 1 year, possibly 
because the cohort included patients with bipolar disorder and overall 
had a considerably worse clinical history with a mean of 7.3 treatment 
failures. Regarding treatment practices in Europe, a long-term study of 
UK TRD patients in routine clinical practice reported an 18-month 
remission rate of 6.5%, decreasing to 4.4% after 42 months (Fonagy 
et al., 2015). Compared with the current study, patients in this cohort 
had a greater mean number of prior treatment failures, as well as greater 
mean current MDE duration. Notwithstanding differences in the base-
line clinical characteristics of these other patient cohorts, the higher 
rates of remission reported in the current study may also be explained by 
low patient numbers at Month 12, possibly reflecting differential loss to 
follow up. In the current study, one third of Month 6 remitters were no 
longer in remission at Month 12, suggesting that treatment efficacy was 
lost. Remission was lost by an even higher proportion of patients (75%) 
between Month 12 and 24 in another observational study, possibly due 
to key differences in the patient baseline characteristics and study, as 
was highlighted above (Dunner et al., 2006). When analyzed in terms of 
response, rather than remission, more than 50.0% of Month 6 re-
sponders lost response by Month 12, suggesting response is a less stable 
outcome for patients than remission. Both analyses support the argu-
ment that current treatment strategies are inadequate to maintain 
long-term treatment success in many TRD patients, but that remission is 
a more robust target outcome than simply response. That remission 
should be the aim of treatment strategies is further supported by the 
greater improvement in functioning/disability in patients who achieved 
remission compared to those who only achieved a response without 
remission in this study. Others have also acknowledged that failure to 
achieve full remission is associated with an increased risk of relapse and 
recurrent episodes, as well as the personal and societal burden resulting 
from residual symptoms (Mendlewicz, 2008; Rush et al., 2006a). 
Despite high levels of non-response, patients continued with phar-
macological treatments for long time periods. The mean length of time on 
the baseline treatment strategy was 220.1 days and after one year, 60.0% 
of patients were still on their first treatment strategy since entering the 
study. Given all patients in this study had already experienced at least two 
treatment failures prior to enrolling, and their continued lack of response, 
this finding is unexpected. The factors that contributed to the continua-
tion of treatments by patients for such long periods in this study are not 
clear. One possibility is that treating physicians have low expectations of 
Fig. 4. Pharmacological treatment duration and time to first treat-
ment change. A. Least square mean plot of treatment number and 
duration, by outcome. Treatment outcome based on MADRS score, or 
CGI-C/S where a MADRS score was unavailable (14/392 [3.6%]). 
Treatment durations were right censored at the time corresponding to 
the last study visit. Since some patients (most likely) continued 
treatment after the study had ended, their treatment durations would 
in fact be longer; this analysis therefore underestimates treatment 
duration. B. Time to first treatment change from study entry (excluded 
treatment lines <30 days in duration and non-pharmacological treat-
ments). Censoring was applied to treatments not stopped at the 
moment corresponding to the last study visit. Response: MADRS 
improvement from baseline ≥50% or MADRS score >10, or (if MADRS 
score unavailable) CGI-C score ≤2 or CGI-S score ≤2; no response: 
MADRS improvement from baseline <50% and MADRS score >10, or 
(if MADRS score unavailable) CGI-C score >2 or CGI-S score >2. CGI- 
C: Clinical Global Impression of Change; CGI-S: Clinical Global 
Impression of Severity; MADRS: Montgomery-Åsberg Depression Rat-
ing Scale.   
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added treatment responses. Following change of treatment strategy, low 
levels of patient response were observed, with only 20.3–25.8% of pa-
tients responding. This was despite a wide range of different treatment 
strategies employed, further indicating the inefficacy of treatment strat-
egy alternatives in this population. 
In the European region, there are few specific recommendations for 
medication strategies to treat TRD as market approval submissions for 
most MDD treatments have not included efficacy and safety studies on 
the TRD subpopulation. An extended-release formulation of quetiapine 
is indicated in the EU for use as an add-on treatment for patients with 
MDD in which a first antidepressant has failed (European Medicines 
Agency, 2020). In December 2019, esketamine nasal spray, an 
N-methyl-D-aspartate receptor (NMDAR) antagonist and new mecha-
nism of action, was granted EU market approval for the treatment of 
TRD in adults, when used in combination with either an SSRI or a SNRI 
(European Medicines Agency, 2020). The same drug had already ob-
tained FDA approval for use in combination with an oral antidepressant 
for TRD earlier that same year (FDA, 2019). In the US, an olanzapi-
ne/fluoxetine hydrochloride combination was granted FDA approval for 
the treatment of TRD in 2009 (FDA, 2020) and aripiprazole and brex-
piprazole are also approved in this indication (FDA, 2020; FDA, 2018). 
However, none of these treatments have EMA approval for use in the 
TRD subpopulation. Since the 1950s, pharmacological treatments for 
MDD have targeted the monoamine pathway (Hillhouse and Porter, 
2015), but the results described here suggest that, for many patients 
with TRD, treatment strategies involving these drugs may be ineffective. 
The poor HRQoL experienced by TRD patients in whom treatment 
continues to be ineffective points to an urgent need for investigators to 
develop alternative treatments for TRD and investigate new treatment 
strategies. A pipeline of drugs to treat MDD are in development that 
target the glutamate pathway. These alternative mechanisms of action 
may open new possibilities for treating TRD, if there is sufficient evi-
dence to support the need for efficacy and safety trials that include the 
TRD subpopulation as a separate entity. 
The data presented here, together with those previously described on 
HRQoL and functionality in TRD in the first paper published from this 
study (Heerlein et al., 2021) demonstrate the substantial impact of TRD 
on patients and society. These data add to the body of real-world evi-
dence demonstrating that treatment strategies currently employed in 
routine clinical practice in Europe, lack efficacy in most patients with 
TRD. 
To allow more in-depth analysis of the relationship between different 
treatment strategies used in routine clinical practice and clinical out-
comes for patients with TRD, it would be valuable to conduct larger- 
scale observational studies with a similar design to the current study. 
As more treatments gain market approval in Europe for TRD specifically, 
it will be important to assess how these impact patient outcomes in a 
real-world setting, beyond the controlled environment of clinical trials. 
Newer treatments require safety and efficacy studies in well-defined 
TRD cohorts to support market approval and improve access to poten-
tially beneficial treatments for these patients. 
4.1. Limitations 
The limitations of the current study include its relatively small size 
compared with other studies, and the absence of a control group to allow 
comparison of the cohort with patients not starting on a new treatment 
strategy. For analysis of treatment strategies, a small proportion of 
outcomes were assigned based on CGI rather than MADRS scores. 
Furthermore, since the number of treatment lines failed prior to enrol-
ment varies across the cohort, the number of treatment changes in the 
study does not relate directly to the total number of treatments a patient 
had been prescribed during the current MDE. As expected in a real-world 
study, patients for whom data were available for analysis decreased over 
time, but this was for many reasons and only a small number were true 
patient drop out. Of note, the study design meant that the later a patient 
enrolled in the study, the less likely they were to reach 12 months before 
the study end date; this was the case for approximately 70% of patients. 
A small proportion of Month 6 or Month 12 visits did not happen within 
the post-study defined cut-off dates, and in those that did, some did not 
have a MADRS score (or other outcome measures) recorded at one or 
more visits. Furthermore, some assessments and/or questionnaires were 
not completed fully, so numbers of responses for some outcome mea-
sures vary. A number of patients were lost to follow up after attending 
only some visits, possibly due to reduced functioning caused by TRD. 
Thus, overall, patient numbers are much lower for analysis of Month 12 
data than for data collected at Month 6, and results for Month 12 should 
therefore be interpreted with caution. Finally, comparisons of patient 
subgroups did not take confounding variables, such as country of origin, 
into account. Importantly, since patient numbers in the study were 
approximately proportional to the population of each country, this led to 
substantial variations in absolute numbers across the countries studied. 
5. Conclusions 
In this study, patients with TRD were treated with many different 
treatment strategies suggesting that there is no consensus on the stan-
dard of care to be used in this population. Despite the wide range of 
treatments used in these patients, treatment response rates were low, 
regardless of the number of treatment steps tried, indicating that overall 
treatment outcomes for patients with TRD are poor. Additionally, data 
presented here suggest that patients may spend a substantial amount of 
time on each treatment without a response. 
Authors’ contributions 
Substantial contributions to study conception and design: KH, GP, 
WH, AJOM, VPS, SR, GR, SM, JM, CV, BG, AHY; substantial contribu-
tions to acquisition, analysis or interpretation of the data: KH, GP, CO, 
TF, GD, WH, AJOM, VPS, SR, GR, SP, SM, JM, CV, BG, AHY; drafting the 
article or revising it critically for important intellectual content: KH, GP, 
CO, TF, GD, WH, AJOM, VPS, SR, GR, SP, SM, JM, CV, BG, AHY; final 
approval of the version of the article to be published: KH, GP, CO, TF, 
GD, WH, AJOM, VPS, SR, GR, SP, SM, JM, CV, BG, AHY. 
Data sharing statement 
Janssen EMEA’s Data Sharing Policy does not include non- 
interventional studies. 
Funding 
This study was sponsored by Janssen EMEA. This article was based 
on the original study 54135419DEP4001 sponsored by Janssen EMEA. 
Support for third-party writing assistance for this article, provided by 
Julia Stevens, Ph.D., and Emma Phillips, Ph.D., Costello Medical, UK, 
was funded by Janssen EMEA in accordance with Good Publication 
Practice (GPP3) guidelines (http://www.ismpp.org/gpp3). 
Disclosures 
KH: Employee of Janssen EMEA 
GP: Grant/research support from Angelini; speaker/consultant for 
Angelini, Janssen, Lundbeck, Neuraxpharm, Sanofi Aventis 
CO: Speaker/consultant for Allergan, Ferring, Fortbildungskolleg, 
Limes Kliniken, MedOnline, Medical Tribune, Neuraxpharm, Sage 
Therapeutics, and Stillachhaus; Research funding from Deutsche For-
schungsgemeinschaft, German Federal Ministry of Education and 
Research and European Union 
TF: Speaker for Janssen-Cilag and Recordati 
GD: Consultant/speaker for AstraZeneca, BMS, Eli Lilly, Euro-
Generics, GSK, Janssen, Lundbeck, Pfizer and Sanofi 
K. Heerlein et al.                                                                                                                                                                                                                                
Journal of Affective Disorders 290 (2021) 334–344
343
WH: Consultant for Janssen 
AJOM: Grants from Schuhfried GmBH, Janssen and Compass Path-
ways, Ltd; investigator-driven research funded by Fundação para Ciên-
cia e Tecnologia (PTDC/MED-NEU/31331/2017), Fundação para 
Ciência e Tecnologia and FEDER (FCT-PTDC/MEC-PSQ/30302/2017- 
IC&DTLISBOA-01-0145-FEDER), the European Commission Horizon 
2020 program (H2020-SC1-2017-CNECT-2-777167-ВΟUNCE; H2020- 
SC1-DTH-2019-875358-FAITH) and the European Research Council 
(grant agreement 950357) 
VPS: Consultancy fees, honoraria or grants from AB-Biotics, Astra-
Zeneca, Bristol-Myers-Squibb, CIBERSAM, Esteve, FIS-ISCiii, Janssen, 
Lundbeck, Otsuka, Pfizer and Servier 
SR: Consultancy fees from Janssen, Lundbeck and Otsuka; grants 
from Janssen 
GR: Speaker/consultant for Angelini, Innova Pharma, Janssen, 
Lundbeck and Otsuka 
SP: Speaker/consultant for Angelini, Janssen, Lundbeck and Sanofi 
SM: Employee of Janssen EMEA 
JM: Employee of Janssen EMEA 
CV: Employee of Janssen EMEA 
BG: Employee of Janssen EMEA 
AHY: Grants from Janssen; speaker/consultant for Allergan, Astra-
Zeneca, Bionomics, Eli Lilly, Janssen, Johnson & Johnson, Livanova, 
Lundbeck, Servier, Sumitomo Dainippon Pharma and Sunovion; inde-
pendent research is funded by the National Institute for Health Research 
(NIHR) Biomedical Research Centre at South London and Maudsley NHS 
Foundation Trust and King’s College London. The views expressed are 
those of the authors and not necessarily those of the NHS, the NIHR, or 
the Department of Health 
Principal investigators and associated study sites 
Belgium: Degraeve, Gunther: Private Practice, G. Degraeve; Domken, 
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Jørgensen, L., Montgomery, S.A., 2013. Extended-release quetiapine fumarate 
(quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to 
antidepressants in patients with treatment-resistant major depressive disorder. 
J Affect Disord 151, 209–219. 
Bennabi, D., Charpeaud, T., Yrondi, A., Genty, J.B., Destouches, S., Lancrenon, S., 
Alaïli, N., Bellivier, F., Bougerol, T., Camus, V., Dorey, J.M., Doumy, O., 
Haesebaert, F., Holtzmann, J., Lançon, C., Lefebvre, M., Moliere, F., Nieto, I., 
Rabu, C., Richieri, R., Schmitt, L., Stephan, F., Vaiva, G., Walter, M., Leboyer, M., El- 
Hage, W., Llorca, P.M., Courtet, P., Aouizerate, B., Haffen, E., 2019. Clinical 
guidelines for the management of treatment-resistant depression: French 
recommendations from experts, the French Association for Biological Psychiatry and 
Neuropsychopharmacology and the fondation FondaMental. BMC Psychiatry 19, 
262. 
Busner, J., Targum, S.D., 2007. The clinical global impressions scale: applying a research 
tool in clinical practice. Psychiatry (Edgmont) 4, 28–37. 
Cavanagh, J.T., Carson, A.J., Sharpe, M., Lawrie, S.M., 2003. Psychological autopsy 
studies of suicide: a systematic review. Psychol Med 33, 395–405. 
Chandler, G.M., Iosifescu, D.V., Pollack, M.H., Targum, S.D., Fava, M., 2010. Validation 
of the Massachusetts General Hospital Antidepressant Treatment History 
Questionnaire (ATRQ). CNS Neurosci Ther 16, 322–325. 
Cleare, A., Pariante, C.M., Young, A.H., Anderson, I.M., Christmas, D., Cowen, P.J., 
Dickens, C., Ferrier, I.N., Geddes, J., Gilbody, S., Haddad, P.M., Katona, C., Lewis, G., 
Malizia, A., McAllister-Williams, R.H., Ramchandani, P., Scott, J., Taylor, D., 
Uher, R., Members of the Consensus Meeting, 2015. Evidence-based guidelines for 
treating depressive disorders with antidepressants: A revision of the 2008 British 
Association for Psychopharmacology guidelines. J Psychopharmacol, 29, 459–525. 
Conway, C.R., George, M.S., Sackeim, H.A., 2017. Toward an Evidence-Based, 
Operational Definition of Treatment-Resistant Depression: When Enough Is Enough. 
JAMA Psychiatry 74, 9–10. 
Dunner, D.L., Rush, A.J., Russell, J.M., Burke, M., Woodard, S., Wingard, P., Allen, J., 
2006. Prospective, long-term, multicenter study of the naturalistic outcomes of 
patients with treatment-resistant depression. J Clin Psychiatry 67, 688–695. 
European Medicines Agency. 2020. Esketamine Summary of Product Characteristics. 
https://www.ema.europa.eu/en/medicines/human/EPAR/spravato. (Accessed 28 
August 2020). 
European Medicines Agency. 2013. Guideline on clinical investigation of medicinal 
products in the treatment of depression. EMA/CHMP/185423/2010 Rev 2. 
European Medicines Agency. 2020. Seroquel SmPC, labelling and package leaflet. htt 
ps://www.ema.europa.eu/en/documents/referral/seroquel-seroquel-xr-associate 
d-names-article-30-referral-annex-iii_en.pdf (Accessed 20 December 2020). 
European Medicines Agency. 2019. Spravato EPAR Product Characteristics. https:// 
www.ema.europa.eu/en/documents/product-information/spravato-epar-product- 
information_en.pdf. (Accessed 31 March 2021). 
Fava, M., Okame, T., Matsushima, Y., Perry, P., Weiller, E., Baker, R.A., 2017. Switching 
from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole 
Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive 
Symptoms and Cognitive and Physical Functioning. Int J Neuropsychopharmacol 20, 
22–30. 
FDA. 2019. Esketamine US Prescribing Information, March 2019. Available at: htt 
ps://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211243lbl.pdf. 
(Accessed 28 August 2020). 
FDA. 2017. Symbyax Prescribing Information. https://www.accessdata.fda.gov/ 
drugsatfda_docs/label/2017/021520s042lbl.pdf. (Accessed 14 April 2021). 
FDA. 2018. Rexulti Prescribing Information. Available at https://www.accessdata.fda. 
gov/drugsatfda_docs/label/2018/205422s003lbl.pdf. (Accessed 20th December 
2020). 
FDA. 2020. Ablify Prescribing Information. https://www.accessdata.fda. 
gov/drugsatfda_docs/label/2020/021436s044s045,021713s035s036,021729s02 
7s028,021866s029s030lbl.pdf. (Accessed 20 December 2020). 
Fonagy, P., Rost, F., Carlyle, J.A., Mcpherson, S., Thomas, R., Pasco Fearon, R.M., 
Goldberg, D., Taylor, D., 2015. Pragmatic randomized controlled trial of long-term 
psychoanalytic psychotherapy for treatment-resistant depression: the Tavistock 
Adult Depression Study (TADS). World Psychiatry 14, 312–321. 
Heerlein, K., Young, A.H., Otte, C., Frodl, T., Degraeve, G., Hagedoorn, W., Oliveira- 
Maia, A.J., Perez Sola, V., Rathod, S., Rosso, G., Sierra, P., Morrens, J., Van 
Dooren, G., Gali, Y., Perugi, G., 2021. Real-world evidence from a European cohort 
study of patients with treatment resistant depression: Baseline patient 
characteristics. J Affect Disorders 283, 115–122. 
Herdman, M., Gudex, C., Lloyd, A., Janssen, M., Kind, P., Parkin, D., Bonsel, G., Badia, X., 
2011. Development and preliminary testing of the new five-level version of EQ-5D 
(EQ-5D-5L). Qual Life Res 20, 1727–1736. 
Hillhouse, T.M., Porter, J.H., 2015. A brief history of the development of antidepressant 
drugs: from monoamines to glutamate. Exp Clin Psychopharmacol 23, 1–21. 
Ionescu, D.F., Rosenbaum, J.F., Alpert, J.E., 2015. Pharmacological approaches to the 
challenge of treatment-resistant depression. Dialogues Clin Neurosci 17, 111–126. 
Jaffe, D.H., Rive, B., Denee, T.R., 2019. The humanistic and economic burden of 
treatment-resistant depression in Europe: a cross-sectional study. BMC Psychiatry 
19, 247. 
James, S.L., Abate, D., Abate, K.H., Abay, S.M., Abbafati, C., Abbasi, N., Abbastabar, H., 
Abd-Allah, F., et al., 2018. Global, regional, and national incidence, prevalence, and 
years lived with disability for 354 diseases and injuries for 195 countries and 
territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 
2017. The Lancet 392, 1789–1858. 
Kim, T., Xu, C., Amsterdam, J.D., 2019. Relative effectiveness of tricyclic antidepressant 
versus monoamine oxidase inhibitor monotherapy for treatment-resistant 
depression. Journal of Affective Disorders 250, 199–203. 
Kubitz, N., Mehra, M., Potluri, R.C., Garg, N., Cossrow, N., 2013. Characterization of 
treatment resistant depression episodes in a cohort of patients from a US commercial 
claims database. PLoS One 8, e76882. 
Lefaucheur, J.P., Aleman, A., Baeken, C., Benninger, D.H., Brunelin, J., Di Lazzaro, V., 
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